New York University Grossman School of Medicine, New York, New York.
VA Boston Health Care System Massachusetts Veterans Epidemiology Research and Information Center, Boston, Massachusetts.
Clin J Am Soc Nephrol. 2022 Oct;17(10):1446-1456. doi: 10.2215/CJN.02160222. Epub 2022 Aug 25.
Contrast-associated AKI may result in higher morbidity and mortality. Intravenous fluid administration remains the mainstay for prevention. There is a lack of consensus on the optimal administration strategy. We studied the association of periprocedure fluid administration with contrast-associated AKI, defined as an increase in serum creatinine of at least 25% or 0.5 mg/dl from baseline at 3-5 days after angiography, and 90-day need for dialysis, death, or a 50% increase in serum creatinine.
DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a secondary analysis of 4671 PRESERVE participants who underwent angiographic procedures. Although fluid type was randomized, strategy of administration was at the discretion of the clinician. We divided the study cohort into quartiles by total fluid volume. We performed multivariable logistic regression, adjusting for clinically important covariates. We tested for the interaction between fluid volume and duration of fluid administration, categorized as <6 or ≥6 hours.
The mean (SD) age was 70 (8) years, 94% of participants were male, and median (interquartile range) eGFR was 60 (41-60) ml/min per 1.73 m. The range of fluid administered was 89-882 ml in quartile 1 and 1258-2790 ml in quartile 4. Compared with the highest quartile (quartile 4) of fluid volume, we found a significantly higher risk of the primary outcome in quartile 1 (adjusted odds ratio, 1.58; 95% confidence interval, 1.06 to 2.38) but not in quartiles 2 and 3 compared with quartile 4. There was no difference in the incidence of contrast-associated AKI across the quartiles. The interaction between volume and duration was not significant for any of the outcomes.
We found that administration of a total volume of 1000 ml, starting at least 1 hour before contrast injection and continuing postcontrast for a total of 6 hours, is associated with a similar risk of adverse outcomes as larger volumes of intravenous fluids administered for periods >6 hours. Mean fluid volumes <964 ml may be associated with a higher risk for the primary outcome, although residual confounding cannot be excluded.
对比剂相关急性肾损伤(contrast-associated AKI)可能导致更高的发病率和死亡率。静脉补液仍然是预防的主要手段。目前,对于最佳补液策略,尚无共识。我们研究了围手术期补液与对比剂相关 AKI 的相关性,后者定义为血管造影后 3-5 天血清肌酐至少升高 25%或 0.5mg/dl,或 90 天内需要透析、死亡或血清肌酐升高 50%。
设计、设置、参与者和测量:我们对接受血管造影程序的 4671 名 PRESERVE 参与者进行了二次分析。尽管液体类型是随机的,但补液策略由临床医生决定。我们根据总液体量将研究队列分为四组。我们进行了多变量逻辑回归分析,调整了重要的临床协变量。我们检测了液体量和液体输注时间(<6 小时或≥6 小时)之间的交互作用。
平均(SD)年龄为 70(8)岁,94%的参与者为男性,中位(四分位间距)eGFR 为 60(41-60)ml/min/1.73m。第 1 组的液体输注范围为 89-882ml,第 4 组为 1258-2790ml。与液体量最高的第 4 组相比,我们发现第 1 组的主要结局风险显著升高(校正比值比,1.58;95%置信区间,1.06 至 2.38),但与第 4 组相比,第 2 组和第 3 组无显著差异。在第 1 至第 4 组之间,对比剂相关 AKI 的发生率没有差异。对于任何结果,体积和持续时间之间的交互作用都不显著。
我们发现,在开始注射对比剂前至少 1 小时给予 1000ml 总液体量,并且在给予对比剂后持续输注 6 小时,与给予>6 小时的较大体积静脉液体相比,不良反应结局的风险相似。尽管不能排除残余混杂因素,但平均液体量<964ml 可能与主要结局风险增加相关。